Mark Orr Email & Phone Number

Seattle, WA, US

Seattle, Washington, United States

Seattle, Washington, United States

Played a crucial role as a core member for six early development project teams for immune cell engager platforms responsible for translational biology and collaborating with leaders from early development project leadership, early clinical development, project management, regulatory, competitive intelligence, commercial and other functions to deliver.

Seattle, Washington, United States

Managed a translational research team of six scientists and senior scientists to develop new combination therapies, identification of novel mechanisms of action, and selection of new indications for early development hematology and oncology biologics including bi- and tri-specific antibodies, including NK cell engagers, T cell engagers, innate immune.

Seattle

- Authored non-clinical pharmacology pre-IND questions to FDA, IND sections 2.6.1, 2.6.2, and 2.6.3, clinical protocol asset background and mechanism of action, and Investigator’s Brochure non-clinical pharmacology content- Directed contract research organization work to demonstrate activity of lead development candidates in patient bone marrow aspirates.

Seattle, WA

Taught course on vaccine adjuvants. Conducted lectures on infectious diseases affecting global health.- Served as a member of the Student Affairs Committee- Mentored students as a member of the Graduate Student Thesis Committee

Greater Seattle Area

Biomarker lead for first-in-class NK cell engager in AML responsible for identifying key biomarkers and assessments to inform clinical development including measurements of activity and modes of action.- Developed Biomarker Implementation Plan- Oversaw developed four novel biomarker assays at contract research organizations- Developed non-clinical.

Greater Seattle Area

Principal Investigator for adjuvanted influenza vaccine development. Small business innovative research grant from the US Centers for Disease Control

Greater Seattle Area

- Co-led vaccine development for enterotoxigenic E. coli with external partners from Sanofi-Pasteur, the Bill & Melinda Gates Foundation, the Naval Medical Research Center, and PATH Vaccine Solutions managing multi-million dollar budget- Awarded R01 grant from NIAID for the development of a nanoparticle alum adjuvant- Awarded research grant from the.

Seattle

- Led a team of researchers performing pre-clinical vaccine development focused on adjuvanted subunit vaccines for tuberculosis- T cell characterization: Flow cytometry, intracellular cytokine staining, in vivo and in vitro cytotoxicity, ELISA, ELISpot- B cell characterization: ASCs, antibody affinity ELISA, flow cytometry- Mechanisms of action of vaccines.

Developed pre-clinical vaccine candidates for tuberculosis

- Cancer Research Institute Fellow studying natural killer and T cell responses to infection with Lewis Lanier.- Awarded American Cancer Society Postdoctoral Fellowship.- Identified a novel signaling pathway for NK cell activation upon viral infection- Elucidated the role of NK cell licensing in response to viral infection

Phd, Immunology

Activities and Societies: Howard Hughes Predoctoral FellowshipThesis Advisor: Christopher B Wilson Elucidating the host-pathogen.

B.S., Acs Chemistry

Activities and Societies: Honors Program Phi Kappa Phi Omicron Delta Kappa